Reyon Pharmaceutical Co Ltd (102460) - Total Liabilities
Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has total liabilities worth ₩239.99 Billion KRW (≈ $162.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Reyon Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Reyon Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Reyon Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Reyon Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lonyer Fuels
SHG:603003
|
China | CN¥501.56 Million |
|
Lu Thai Textile
SHE:200726
|
China | HK$3.85 Billion |
|
Texaf SA
BR:TEXF
|
Belgium | €58.31 Million |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
Mexico | MX$407.26 Million |
|
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
|
USA | $80.89 Million |
|
Atlas Lithium Corporation Common Stock
NASDAQ:ATLX
|
USA | $35.17 Million |
|
Manulife Holdings Bhd
KLSE:1058
|
Malaysia | RM6.59 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Reyon Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Reyon Pharmaceutical Co Ltd (102460) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Reyon Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total liabilities of Reyon Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩250.05 Billion ≈ $169.46 Million |
-0.44% |
| 2023-12-31 | ₩251.15 Billion ≈ $170.20 Million |
+6.00% |
| 2022-12-31 | ₩236.93 Billion ≈ $160.56 Million |
+1.80% |
| 2021-12-31 | ₩232.74 Billion ≈ $157.73 Million |
+165.93% |
| 2020-12-31 | ₩87.52 Billion ≈ $59.31 Million |
+67.69% |
| 2019-12-31 | ₩52.19 Billion ≈ $35.37 Million |
-32.90% |
| 2018-12-31 | ₩77.77 Billion ≈ $52.71 Million |
+9.27% |
| 2017-12-31 | ₩71.18 Billion ≈ $48.24 Million |
+133.83% |
| 2016-12-31 | ₩30.44 Billion ≈ $20.63 Million |
-0.42% |
| 2012-12-31 | ₩30.57 Billion ≈ $20.72 Million |
+6.39% |
| 2011-12-31 | ₩28.73 Billion ≈ $19.47 Million |
+29.70% |
| 2009-12-31 | ₩22.15 Billion ≈ $15.01 Million |
-2.14% |
| 2008-12-31 | ₩22.64 Billion ≈ $15.34 Million |
-- |
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more